Bausch + Lomb Swings To Profit In Q3, Lifts FY26 Guidance; Pre-market Shares Up

Bausch + Lomb (BLCO) reported a Q3 2026 profit of $32M ($0.09/Share) vs. a loss last year, with revenue up 7% to $1.38B. Guidance raised: FY26 revenue now $5.45B-$5.55B, adjusted EBITDA $1.09B-$1.14B. Pre-market shares up 2.1%.

Original reporting
Published Oct 28, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BLCO
Bullish
high confidence
Mentioned
$BLCO
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$BLCOBullishMed
01

Why it matters

The key market catalyst is the combination of a Q3 profit swing and raised FY26 revenue and adjusted EBITDA guidance ranges, which can change FY26 earnings power expectations.

02

Market read

This is a direct earnings-and-guidance update with specific FY26 ranges, making it actionable for near-term positioning and expectation-setting.

03

What to watch

Traders may discount the adjusted EBITDA metric if it excludes items investors view as recurring, and will watch whether segment growth (Vision Care, Surgical, Pharmaceuticals) is sustainable into FY26.

Relevance 9/10Novelty 8/10Timing: pre-market today

Background

Bausch + Lomb is a global eye-care company reporting quarterly results by Vision Care, Surgical, and Pharmaceuticals segments.

Company-level read

Ticker impact

$BLCOBullishHigh confidence
Context

Bausch + Lomb reported Q3 fiscal 2026 return to profit and raised FY26 revenue and adjusted EBITDA guidance in pre-market trading.

Expected impact

Likely upward pressure as the market reprices FY26 revenue and adjusted EBITDA expectations after the guidance raise.

Evidence & confidence

The article discloses a profit swing (net income vs prior-year loss) plus higher full-year revenue and adjusted EBITDA ranges, which are direct valuation drivers.

Market effects

Positive read-through for managed-care and eye-care peers if investors broaden to profitability and margin improvement narratives.

Limited, primarily US-listed healthcare/consumer health sentiment.

Low; guidance is company-specific with no stated cross-border policy or supply shock.

Counterpoint

The guidance ranges are only modestly higher, so the stock may fade if investors expected a larger step-up or if margins depend on temporary operating efficiencies.

Key entities

  • Bausch + Lomb Corp.

    Reported Q3 fiscal 2026 profitability and lifted FY26 revenue and adjusted EBITDA guidance ranges.

  • New York Stock Exchange

    Shares were trading about 2.10% higher in pre-market hours per the article.

Related articles

$BLCOMedAI 8/10

Bausch + Lomb (BLCO) BL1332 Misses Phase 2 Primary Endpoint

Bausch + Lomb's (BLCO) Phase 2 study for BL1332 missed its primary endpoint, showing no statistically significant improvement over the vehicle. The LS mean differences were -11.5 and -9.0, favoring BL1332 but not reaching significance. A 0.30% dose showed nominal significance at six hours for a secondary endpoint, with adverse event rates reported but no serious events.

$BLCOMedAI 8/10

What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call

Bausch + Lomb (BLCO) reported Q3 earnings, highlighting growth across multiple franchises. Adjusted gross margin rose to 64.7%, with operating cash flow at $233M. The company raised its 2026 revenue outlook to $5.45B-$5.55B and adjusted EBITDA guidance to $1.09B-$1.14B. Interim CEO Appio focused on profitability and R&D pipeline advancements.

$BLCOHighAI 8/10

Bausch & Lomb Corp (BLCO) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth

Bausch & Lomb Corp (BLCO) reported Q3 2026 revenue growth of 8%, with all segments showing gains. Adjusted EBITDA rose 34% to $325M. The company raised full-year revenue and EBITDA guidance. Key products like MIBO and Lumify saw strong growth, while surgical equipment revenue declined 11%. The company faces regulatory and competitive pressures. Leadership changes were announced, with Tom Appio becoming interim CEO.

$BLCOHighAI 8/10

Bausch + Lomb Soars 16% on Big Q3 Profit Beat and Raised Full-Year Guidance

Bausch + Lomb's shares rose 16% after Q3 earnings beat expectations, with adjusted EPS at $0.34 vs. $0.22 consensus and revenue up 7% to $1.375B. Adjusted EBITDA increased 34% to $325M, and the company raised its full-year EBITDA guidance by $65M. Key growth drivers included MIEBO, LUMIFY, and premium intraocular lenses. Johnson & Johnson's contact lens sales also grew, contrasting with Cooper Companies' flat sales.